Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMGO7QT)

Drug Name	INK128 DMGO7QT
Synonyms	1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Multiple myeloma	DISEWP9B	2A83	Phase 2	[1]
Breast cancer	DIS7DPX1	2C60-2C65	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02244463) A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)